sp-3164
salarius pharma
['multiplemyeloma', 'sp-3164', 'salarius']
tomorrow, aundrietta d. duncan, phd presents exciting data on sp-3164 s anti-cancer activity in #multiplemyeloma. join her during 's 2023 annual meeting to see the molecular glue s potential as a novel #cancertreatment. abstract: 
Salarius is a cancer-focused biotechnology company. Currently in clinical trials for Ewing Sarcoma w/ Orphan Drug & Rare Pediatric Disease Designation.